Related references
Note: Only part of the references are listed.An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients
James Gilleen et al.
PSYCHOPHARMACOLOGY (2021)
Glutamate in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: A Meta-analysis of 1H-Magnetic Resonance Spectroscopy Studies
Jakob Kaminski et al.
BIOLOGICAL PSYCHIATRY (2021)
The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial
James Gilleen et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts cognitive deficits induced by the D1/D2 dopaminergic receptor agonist apomorphine in rats
Nikolaos Pitsikas et al.
PSYCHOPHARMACOLOGY (2021)
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator (D1PAM), in Healthy Subjects
Darren Wilbraham et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
LL-00066471, a novel positive allosteric modulator of α7 nicotinic acetylcholine receptor ameliorates cognitive and sensorimotor gating deficits in animal models: Discovery and preclinical characterization
Mahip K. Verma et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain
Caterina Montani et al.
NEUROPSYCHOPHARMACOLOGY (2021)
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Plinio C. Casarotto et al.
CELL (2021)
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
Ramakrishna Nirogi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
Not Just a Bystander: The Emerging Role of Astrocytes and Research Tools in Studying Cognitive Dysfunctions in Schizophrenia
Chia-Yuan Chang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials
Daniel Prates Baldez et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2021)
Prolactin, metabolic and immune parameters in naive subjects with a first episode of psychosis
Clemente Garcia-Rizo et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2021)
Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review
Caitlin O. B. Yolland et al.
NUTRITIONAL NEUROSCIENCE (2020)
Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia
Jochen Kindler et al.
MOLECULAR PSYCHIATRY (2020)
The association of cognitive performance and IL-6 levels in schizophrenia is influenced by age and antipsychotic treatment
Rafael Ribeiro-Santos et al.
NORDIC JOURNAL OF PSYCHIATRY (2020)
A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects
Deborah A. Yurgelun-Todd et al.
PSYCHOPHARMACOLOGY (2020)
Antipsychotic-like profile of CIQ isomers in animal models of schizophrenia
Pushparaj Gawai et al.
BEHAVIOURAL PHARMACOLOGY (2020)
Inhibition of calcium-calmodulin-dependent phosphodiesterase (PDE1) suppresses inflammatory responses
Jennifer J. O'Brien et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2020)
Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management
Kevin C. F. Fone et al.
MOLECULAR NEUROBIOLOGY (2020)
Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis
Timothy Tanzer et al.
PSYCHOPHARMACOLOGY (2020)
Profile of cognitive deficits in schizophrenia and factor structure of the Czech MATRICS Consensus Cognitive Battery
Ondrej Bezdicek et al.
SCHIZOPHRENIA RESEARCH (2020)
Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study
Kate Merritt et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
The muscarinic M-1 receptor modulates associative learning and memory in psychotic disorders
Geor Bakker et al.
NEUROIMAGE-CLINICAL (2020)
Association of DTNBP1 With Schizophrenia: Findings From Two Independent Samples of Han Chinese Population
Yongfeng Yang et al.
FRONTIERS IN PSYCHIATRY (2020)
One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia
Luyao Xia et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia
Mayasah Y. Al-Nema et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2020)
Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation
Rouba Kozak et al.
FRONTIERS IN PHARMACOLOGY (2020)
Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection
Federica Bono et al.
BIOMOLECULES (2020)
Identificacion of MRI-based psychosis subtypes: Replication and refinement
Alvaro Planchuelo-Gomez et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2020)
Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats
Misae Takakuwa et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2020)
Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement
Maju Mathew Koola et al.
PSYCHIATRY RESEARCH (2020)
Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia
Cassandra J. Hatzipantelis et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
Sebastiano Alfio Torrisi et al.
PHARMACEUTICALS (2020)
Aberrant striatal dopamine links topographically with cortico-thalamic dysconnectivity in schizophrenia
Mihai Avram et al.
BRAIN (2020)
Mapping Convergent and Divergent Cortical Thinning Patterns in Patients With Deficit and Nondeficit Schizophrenia
Teng Xie et al.
SCHIZOPHRENIA BULLETIN (2019)
An Overview of Animal Models Related to Schizophrenia
Ian R. Winship et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2019)
A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia
Thomas A. Macek et al.
SCHIZOPHRENIA RESEARCH (2019)
Positive and negative symptoms in schizophrenia: A longitudinal analysis using latent variable structural equation modelling
Giuseppe Carra et al.
SCHIZOPHRENIA RESEARCH (2019)
Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens
Daniel F. Manvich et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Raloxifene as a treatment for cognition in women with schizophrenia: the influence of menopause status
C. Gurvich et al.
PSYCHONEUROENDOCRINOLOGY (2019)
Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms
Mihai Avram et al.
BRAIN (2019)
The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders
Javier Labad
PSYCHONEUROENDOCRINOLOGY (2019)
TWO GLOBAL PHASE III TRIALS OF ENCENICLINE FOR COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA PATIENTS: RED FLAGS AND LESSONS LEARNED
Stephen Brannan
SCHIZOPHRENIA BULLETIN (2019)
Schizophrenia Exhibits Bi-directional Brain-Wide Alterations in Cortico-Striato-Cerebellar Circuits
Jie Lisa Ji et al.
CEREBRAL CORTEX (2019)
Reversal of MK-801-Induced Disruptions in Social Interactions and Working Memory with Simultaneous Administration of LY487379 and VU152100 in Mice
Paulina Cieslik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials
Wei Zheng et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2019)
Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis
Emre Bora
PSYCHOLOGICAL MEDICINE (2019)
A Natural Product with High Affinity to Sigma and 5-HT7 Receptors as Novel Therapeutic Drug for Negative and Cognitive Symptoms of Schizophrenia
Lien Wang et al.
NEUROCHEMICAL RESEARCH (2019)
A Novel Phosphodiesterase 1 Inhibitor DSR-141562 Exhibits Efficacies in Animal Models for Positive, Negative, and Cognitive Symptoms Associated with Schizophrenia
Takeshi Enomoto et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
The mGluR2/3 agonist LY379268 reverses NMDA receptor antagonist effects on cortical gamma oscillations and phase coherence, but not working memory impairments, in mice
Elysia Sokolenko et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia
Lulu Zhang et al.
SCHIZOPHRENIA RESEARCH (2019)
In Vivo Modulation of Hippocampal Excitability by M4 Muscarinic Acetylcholine Receptor Activator: Implications for Treatment of Alzheimer's Disease and Schizophrenic Patients
Michael Popiolek et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis
Farivar Fathian et al.
ACTA NEUROPSYCHIATRICA (2019)
GABA releases from parvalbumin-expressing and unspecific GABAergic neurons onto CA1 pyramidal cells are differentially modulated by presynaptic GABAB receptors in mouse hippocampus
Yingqian Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2-and α7-nicotinic acetylcholine receptors
Agnieszka Potasiewicz et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia
Ye Yang et al.
PSYCHIATRY RESEARCH (2019)
Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc-
Motohiro Okada et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
The therapeutic effect of quetiapine on cognitive impairment associated with 5-HT1A presynaptic receptor involved schizophrenia
Dai Han et al.
JOURNAL OF INTEGRATIVE NEUROSCIENCE (2019)
Modafinil for people with schizophrenia or related disorders
Javier Ortiz-Orendain et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set
Guillaume Fond et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2018)
Rare disruptive variants in the DISC1 Interactome and Regulome: association with cognitive ability and schizophrenia
S. Teng et al.
MOLECULAR PSYCHIATRY (2018)
N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
Philippe Conus et al.
SCHIZOPHRENIA BULLETIN (2018)
A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity
Jerri M. Rook et al.
ACS CHEMICAL NEUROSCIENCE (2018)
GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia
Meng-yi Xu et al.
ACTA PHARMACOLOGICA SINICA (2018)
Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine
Indrani Poddar et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Medication adherence in patients with schizophrenia: a qualitative study of the patient process in motivational interviewing
Jos Dobber et al.
BMC PSYCHIATRY (2018)
Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways
Benneth Ben-Azu et al.
BRAIN RESEARCH BULLETIN (2018)
Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery
Agnieszka Zagorska et al.
CURRENT MEDICINAL CHEMISTRY (2018)
Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia
Mayako Yamazaki et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2018)
The effects of chronic stress on the human brain: From neurotoxicity, to vulnerability, to opportunity
Sonia J. Lupien et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2018)
Efficacy and Safety of the alpha(7)-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers
George M. Haig et al.
JOURNAL OF CLINICAL PSYCHIATRY (2018)
Mechanisms underlying the role of DISC1 in synaptic plasticity
Daniela Tropea et al.
JOURNAL OF PHYSIOLOGY-LONDON (2018)
Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β
Bo Xing et al.
NEUROPHARMACOLOGY (2018)
HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice
Mario de la Fuente Revenga et al.
NEUROSCIENCE (2018)
Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis
Virginia Soria et al.
PSYCHONEUROENDOCRINOLOGY (2018)
Cognitive Deficits in Schizophrenia: Understanding the Biological Correlates and Remediation Strategies
Adarsh Tripathi et al.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2018)
Cognitive Function and Serum Hormone Levels Are Associated with Gray Matter Volume Decline in Female Patients with Prolactinomas
Shun Yao et al.
FRONTIERS IN NEUROLOGY (2018)
Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway
Hebatalla I. Ahmed et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2018)
Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: A secondary outcome analysis of the OFFER randomized controlled study
Tomasz Pawelczyk et al.
SCHIZOPHRENIA RESEARCH (2018)
In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study
P. W. Chiu et al.
SCHIZOPHRENIA RESEARCH (2018)
Schizophrenia-related dysbindin-1 gene is required for innate immune response and homeostasis in the developing subventricular zone
Abeer R. Al-Shammari et al.
NPJ SCHIZOPHRENIA (2018)
An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil
Eric Murillo-Rodriguez et al.
ACS CHEMICAL NEUROSCIENCE (2018)
Changes in Serine Racemase-Dependent Modulation of NMDA Receptor: Impact on Physiological and Pathological Brain Aging
Jean-Marie Billard
FRONTIERS IN MOLECULAR BIOSCIENCES (2018)
Prefrontal dysconnectivity links to working memory deficit in first-episode schizophrenia
Xiaojing Fang et al.
BRAIN IMAGING AND BEHAVIOR (2018)
D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity
Donald C. Goff
CURRENT NEUROPHARMACOLOGY (2017)
Hormone-replacement therapy: current thinking
Roger A. Lobo
NATURE REVIEWS ENDOCRINOLOGY (2017)
Cognitive effects of adjunctive N-acetyl cysteine in psychosis
M. Rapado-Castro et al.
PSYCHOLOGICAL MEDICINE (2017)
Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy
Hikaru Hori et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2017)
Potassium channel gene associations with joint processing speed and white matter impairments in schizophrenia
H. A. Bruce et al.
GENES BRAIN AND BEHAVIOR (2017)
Theranostic Biomarkers for Schizophrenia
Matea Nikolac Perkovic et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation
Alexandre V. Ivachtchenko et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial
Mark Weiser et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia: Unexpected Sex-Related Effects (Double-Blind Placebo-Controlled Trial)
Margarita Morozova et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2017)
Neurophysiological Effects of Bitopertin in Schizophrenia
Joshua T. Kantrowitz et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2017)
Relationships between dorsolateral prefrontal cortex metabolic change and cognitive impairment in first-episode neuroleptic-naive schizophrenia patients
Man-Li Huang et al.
MEDICINE (2017)
Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects
Daisuke Ibi et al.
NATURE NEUROSCIENCE (2017)
A review of molecular genetic studies of neurocognitive deficits in schizophrenia
Gwyneth Zai et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2017)
Negative symptoms: History of the concept and their position in diagnosis of schizophrenia
Sonia Dollfus et al.
SCHIZOPHRENIA RESEARCH (2017)
The neurodevelopmental origins of schizophrenia in the penumbra of genomic medicine
Daniel R. Weinberger
WORLD PSYCHIATRY (2017)
Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia A Meta-analysis
Stefan P. Brugger et al.
JAMA PSYCHIATRY (2017)
Activation and Desensitization Mechanism of AMPA Receptor-TARP Complex by Cryo-EM
Shanshuang Chen et al.
CELL (2017)
Classics in Chemical Neuroscience: Aripiprazole
Austen B. Casey et al.
ACS CHEMICAL NEUROSCIENCE (2017)
Serotonin 5-HT7 Receptor in the Ventral Hippocampus Modulates the Retrieval of Fear Memory and Stress-Induced Defecation
Yu Ohmura et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume
S. G. Fillman et al.
MOLECULAR PSYCHIATRY (2016)
Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys
Alvin V. Terry et al.
PSYCHOPHARMACOLOGY (2016)
Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice
Lakshmi Rajagopal et al.
PSYCHOPHARMACOLOGY (2016)
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia
David Walling et al.
SCHIZOPHRENIA BULLETIN (2016)
Effects of the metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on rats tested with the paired associates learning task in touchscreen-equipped operant conditioning chambers
Brittney R. Lins et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases
Bassem Sadek et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
GM1 ganglioside reverses the cognitive deficits induced by MK801 in mice
Yu-Fei Ni et al.
BEHAVIOURAL PHARMACOLOGY (2016)
Effects of 5-HT-7 receptor ligands on memory and cognition
Nicholas Zareifopoulos et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2016)
The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia
Agnieszka Nikiforuk et al.
NEUROPHARMACOLOGY (2016)
Selective activation of α7 nicotinic acetylcholine receptors augments hippocampal oscillations
Milan Stoiljkovic et al.
NEUROPHARMACOLOGY (2016)
Reduced Labeling of Parvalbumin Neurons and Perineuronal Nets in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia
John F. Enwright et al.
NEUROPSYCHOPHARMACOLOGY (2016)
The effect of combined treatment with escitalopram and risperidone on the MK-801-induced changes in the object recognition test in mice
Zofia Rogoz et al.
PHARMACOLOGICAL REPORTS (2016)
Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial
Robert C. Smith et al.
PLOS ONE (2016)
The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia
Linda J. Bristow et al.
PLOS ONE (2016)
Cognitive impairment and cortisol levels in first-episode schizophrenia patients
David Havelka et al.
STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS (2016)
Antioxidant treatments for schizophrenia
Pedro V. S. Magalhaes et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Meta-Analysis of Functional Neuroimaging and Cognitive Control Studies in Schizophrenia: Preliminary Elucidation of a Core Dysfunctional Timing Network
Irene Alustiza et al.
FRONTIERS IN PSYCHOLOGY (2016)
Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials
R. E. Nielsen et al.
ACTA PSYCHIATRICA SCANDINAVICA (2015)
The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia
Corinne Beinat et al.
CNS DRUGS (2015)
Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction
Marlies Van Duinen et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
The role of nitric oxide donors in schizophrenia: Basic studies and clinical applications
Nikolaos Pitsikas
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Negative modulation of α5 GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion
Tamara Timic Stamenic et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia
T. W. Weickert et al.
MOLECULAR PSYCHIATRY (2015)
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia
Weixing Shen et al.
NEURON (2015)
Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement
Mei Huang et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2015)
Effects of ziprasidone, SCH23390 and SB277011 on spatial memory in the Morris water maze test in naive and MK-801 treated mice
Pelin Tanyeri et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2015)
Catechol-O-methyltransferase genotype and response to Compensatory Cognitive Training in outpatients with schizophrenia
Cynthia Z. Burton et al.
PSYCHIATRIC GENETICS (2015)
Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms
Germana Silva Vasconcelos et al.
SCHIZOPHRENIA RESEARCH (2015)
Investigation of gene effects and epistatic interactions between Akt1 and neuregulin 1 in the regulation of behavioral phenotypes and social functions in genetic mouse models of schizophrenia
Ching-Hsun Huang et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2015)
Cognitive Effects of Very Low Nicotine Content Cigarettes, With and Without Nicotine Replacement, in Smokers With Schizophrenia and Controls
Christopher G. AhnAllen et al.
NICOTINE & TOBACCO RESEARCH (2015)
Investigating schizophrenia in a “dish”: possibilities, potential and limitations
NICHOLAS J. BRAY et al.
World Psychiatry (2015)
A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
AnnCatherine M. Downing et al.
BMC PSYCHIATRY (2014)
Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration
Mrinrnay Chakrabarti et al.
BRAIN RESEARCH BULLETIN (2014)
Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study
Margarita A. Morozova et al.
CNS SPECTRUMS (2014)
Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia
Douglas Boggs et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis
G. Desamericq et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia
Mayako Yamazaki et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Reboxetine Adjuvant Therapy in Patients With Schizophrenia Showing a Suboptimal Response to Clozapine A 12-Week, Open-Label, Pilot Study
Antonio Bruno et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT) 2A and DA D2 antagonism and 5-HT1A partial agonism
Mei Huang et al.
JOURNAL OF NEUROCHEMISTRY (2014)
Neuroanatomical phenotypes in a mouse model of the 22q11.2 microdeletion
J. Ellegood et al.
MOLECULAR PSYCHIATRY (2014)
Increased Prolactin Levels Are Associated with Impaired Processing Speed in Subjects with Early Psychosis
Itziar Montalvo et al.
PLOS ONE (2014)
The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia
Agnieszka Nikiforuk
REVIEWS IN THE NEUROSCIENCES (2014)
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia
Christine E. Marx et al.
PSYCHOPHARMACOLOGY (2014)
The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens
Mei Huang et al.
PSYCHOPHARMACOLOGY (2014)
A Randomized Trial of the Efficacy and Safety of the H3 Antagonist ABT-288 in Cognitive Impairment Associated With Schizophrenia
George M. Haig et al.
SCHIZOPHRENIA BULLETIN (2014)
Antidepressants for cognitive impairment in schizophrenia - A systematic review and meta-analysis
Jeffrey A. Vernon et al.
SCHIZOPHRENIA RESEARCH (2014)
Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia
Maju Mathew Koola et al.
SCHIZOPHRENIA RESEARCH (2014)
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial
Fang Liu et al.
SCHIZOPHRENIA RESEARCH (2014)
The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity
Thomas E. Chater et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2014)
Multivariate neuroanatomical classification of cognitive subtypes in schizophrenia: A support vector machine learning approach
Ian C. Gould et al.
NEUROIMAGE-CLINICAL (2014)
Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study
Weiwei Zhu et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2014)
Update on Typical and Atypical Antipsychotic Drugs
Herbert Y. Meltzer
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
HDAC2 as a new target to improve schizophrenia treatment
Mitsumasa Kurita et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2013)
Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia
C. S. Weickert et al.
MOLECULAR PSYCHIATRY (2013)
Role of presynaptic metabotropic glutamate receptors in the induction of long-term synaptic plasticity of vesicular release
Chirag Upreti et al.
NEUROPHARMACOLOGY (2013)
The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey
Sean M. Smith et al.
NEUROPHARMACOLOGY (2013)
Effects of the Selective 5-HT7 Receptor Antagonist SB-269970 and Amisulpride on Ketamine-Induced Schizophrenia-like Deficits in Rats
Agnieszka Nikiforuk et al.
PLOS ONE (2013)
Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine
Nicholas E. Clifton et al.
PSYCHOPHARMACOLOGY (2013)
Brain Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 Subjects
Sander V. Haijma et al.
SCHIZOPHRENIA BULLETIN (2013)
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
Melissa A. Snyder et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2013)
Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls
Xiang Yang Zhang et al.
HUMAN GENETICS (2012)
BL-1020, a New γ-Aminobutyric Acid–Enhanced Antipsychotic
Yona Geffen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Modafinil Reverses Phencyclidine-Induced Deficits in Cognitive Flexibility, Cerebral Metabolism, and Functional Brain Connectivity
Neil Dawson et al.
SCHIZOPHRENIA BULLETIN (2012)
Acetylcholinesterase inhibitors for schizophrenia
Jasvinder Singh et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
The influence of N-desmethylclozapine and clozapine on recognition memory and BDNF expression in hippocampus
Aygun Ertugrul et al.
BRAIN RESEARCH BULLETIN (2011)
Animal models of schizophrenia
C. A. Jones et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Effects of the Putative Cognitive-Enhancing Ampakine, CX717, on Attention and Object Recognition Memory
Yiwen Zheng et al.
CURRENT ALZHEIMER RESEARCH (2011)
The Chandelier Neuron in Schizophrenia
David A. Lewis
DEVELOPMENTAL NEUROBIOLOGY (2011)
Multiple Origins of the Cortical Gamma Rhythm
Miles A. Whittington et al.
DEVELOPMENTAL NEUROBIOLOGY (2011)
Stress and Inflammation Reduce Brain-Derived Neurotrophic Factor Expression in First-Episode Psychosis: A Pathway to Smaller Hippocampal Volume
Valeria Mondelli et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Phencyclidine-induced Loss of Asymmetric Spine Synapses in Rodent Prefrontal Cortex is Reversed by Acute and Chronic Treatment with Olanzapine
John D. Elsworth et al.
NEUROPSYCHOPHARMACOLOGY (2011)
PREGNENOLONE AS A NOVEL THERAPEUTIC CANDIDATE IN SCHIZOPHRENIA: EMERGING PRECLINICAL AND CLINICAL EVIDENCE
C. E. Marx et al.
NEUROSCIENCE (2011)
Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis
M. Aas et al.
PSYCHOLOGICAL MEDICINE (2011)
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Korrapati V. Sathyasaikumar et al.
SCHIZOPHRENIA BULLETIN (2011)
Alterations in Metabotropic Glutamate Receptor 1α and Regulator of G Protein Signaling 4 in the Prefrontal Cortex in Schizophrenia
David W. Volk et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Meta-Analysis of Genetic Variation in DTNBP1 and General Cognitive Ability
Jian-Ping Zhang et al.
BIOLOGICAL PSYCHIATRY (2010)
Pregnenolone and Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia and Schizoaffective Disorder: An 8-Week, Double-Blind, Randomized, Controlled, 2-Center, Parallel-Group Trial
Michael S. Ritsner et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality
Andrew J. Bradley et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis
Valeria Mondelli et al.
SCHIZOPHRENIA RESEARCH (2010)
Neuroanatomic and cognitive abnormalities related to herpes simplex virus type 1 in schizophrenia
David J. Schretlen et al.
SCHIZOPHRENIA RESEARCH (2010)
Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases
C. Y. Jin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia
Robert R. Conley et al.
CLINICAL NEUROPHARMACOLOGY (2009)
GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice
Sawako Arai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia
Yona Geffen et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
Neurocognition in First-Episode Schizophrenia: A Meta-Analytic Review
Raquelle I. Mesholam-Gately et al.
NEUROPSYCHOLOGY (2009)
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
Christine E. Marx et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Dysbindin regulates hippocampal LTP by controlling NMDA receptor surface expression
Tina Tze-Tsang Tang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
Anantha Shekhar et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder
Harvey M. Morris et al.
CEREBRAL CORTEX (2008)
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects
Abraham Nudelman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Association between genetic variants of IL-1 beta, IL-6 and TNF-alpha cytokines and cognitive performance in the elderly general population of the MEMO-study
Bernhard T. Baune et al.
PSYCHONEUROENDOCRINOLOGY (2008)
Estrogen and Comprehension of Metaphoric Speech in Women Suffering From Schizophrenia: Results of a Double-Blind, Placebo-Controlled Trial
Niels Bergemann et al.
SCHIZOPHRENIA BULLETIN (2008)
Modafinil: A review of neurochemical actions and effects on cognition
Michael J. Minzenberg et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Disrupted in schizophrenia 1 and phosphodiesterase 413: towards an understanding of psychiatric illness
J. Kirsty Millar et al.
JOURNAL OF PHYSIOLOGY-LONDON (2007)
Group II metabotropic glutamate receptors inhibit glutamate release at thalamocortical synapses in the developing somatosensory cortex
Z. Mateo et al.
NEUROSCIENCE (2007)
AKT1 and neurocognition in schizophrenia
Andrea Poyastro Pinheiro et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2007)
Treatment of cognitive deficits associated with schizophrenia - Potential role of catechol-O-methyltransferase inhibitors
Jose A. Apud et al.
CNS DRUGS (2007)
Molecular targets for treating cognitive dysfunction in schizophrenia
John A. Gray et al.
SCHIZOPHRENIA BULLETIN (2007)
Impairments in frontal cortical γ synchrony and cognitive control in schizophrenia
R. Y. Cho et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia - A randomized, double-blind, placebo-controlled, crossover trial
Michael S. Ritsner et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers
Beng-Choon Ho et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series
S Marenco et al.
SCHIZOPHRENIA RESEARCH (2002)
Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients
MR Gluck et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition
AK Malhotra et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment
T Sumiyoshi et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia
DC Goff et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia
T Sumiyoshi et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2000)
Decreased glutamic acid decarboxylase(67) messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia
DW Volk et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Share Paper
